Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.M. Yancik, L.A.G. Ries.
Aging and cancer in America. Demographic and epidemiologic perspectives.
Hematol/Oncol Clin N Am, 14 (2000), pp. 17-23
[2.]
National Center for Health Statistics.
Vital statistics of the United States 1989 Mortality- part B.
[3.]
L. Balducci.
Geriatric oncology.
Clin Rev Oncol Hematol, 46 (2003), pp. 211-220
[4.]
L. Balducci.
Guidelines for the management of the older cancer patient [en prensa].
J NCCN, (2004),
[5.]
L. Repetto, L. Biganzoli, C.H. Koehne, et al.
Cancer in the elderly. Task force guidelines for the use of growth factors in elderly patients with cancer.
Eur J Cancer, 39 (2003), pp. 3364-3372
[6.]
C. Boult, L.B. Boult, L. Morishit, et al.
A randomized clinical trial of outpatient geriatric evaluation and management.
J Am Ger Soc, 49 (2001), pp. 351-359
[7.]
A.E. Stuck, A.L. Siu, G.D. Wieland, et al.
Comprehensive geriatric assessment: meta-analysis of controlled trials.
Lancet, 342 (1993), pp. 1032-1036
[8.]
D.B. Reuben, J. Franck, S. Hirsch, et al.
A randomized clinical trial of outpatient geriatric assessment (CGA), coupled with an intervention, to increase adherence to recommendations.
J Am Ger Soc, 47 (1999), pp. 269-276
[9.]
C.J. Bula, A.C. Berod, A.E. Stuck, et al.
Effectiveness of preventive in-home geriatric assessment in well functioning, community dwelling older people: secondary analysis of a randomized trial.
J Am Ger Soc, 47 (1999), pp. 389-395
[10.]
F. Landi, G. Onder, A. Russo, et al.
A new model for integrated home care in the elderly: impact on hospital use.
J Clin Epidemiol, 54 (2001), pp. 968-970
[11.]
R. Bernabei, V. Venturiero, P. Tarsitani, et al.
The comprehensive geriatric assessment: when, where, how.
Crit Rev Hematol Oncol, 33 (2000), pp. 45-56
[12.]
H.J. Cohen, J.R. Feussner, M. Weinberger, et al.
A controlled trial of inpatient and outpatient geriatric evaluation and management.
N Engl J Med, 346 (2002), pp. 905-912
[13.]
L. Repetto, L. Fratino, R.A. Audisio, et al.
Comprehensive geriatric assessment adds information to the Eastern Cooperative group Performance Status in Elderly cáncer patients. An Italian Group for Geriatric Oncology Study.
J Clin Oncol, 20 (2002), pp. 494-502
[14.]
S.S. Ingram, P.H. Seo, R.E. Martell, et al.
Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology.
J Clin Oncol, 20 (2002), pp. 770-775
[15.]
M. Extermann, J. Overcash, G.H. Lyman, et al.
Comorbidity and functional status are independent in older cancer patients.
J Clin Oncol, 16 (1998), pp. 1582-1587
[16.]
D.G. Blazer, C.F. Hybels, C.F. Pieper.
The association of depression and mortality in elderly persons: a case for multiple independent pathways.
J Gerontol Med Sci, 56 (2001), pp. M505-M509
[17.]
L. Balducci.
Anemia in the older person: epidemiologic and clinical considerations.
J Am Ger Soc, (2003), pp. 1-7
[18.]
L. Balducci.
Anemia, cancer and aging.
Cancer Control, 10 (2003), pp. G478-G486
[19.]
J.M. Lyness, D.A. Ling, C. Cox, et al.
The importance of subsyndromal depression in older primary care patients. Prevalence and associated functional disability.
J Am Ger Soc, 47 (1999), pp. 647-652
[20.]
M.J. Ratain, R.L. Schilsky, K.E. Choi, et al.
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
Clin Pharmacol Ther, 45 (1989), pp. 226-233
[21.]
J.H. Silber, M. Fridman, R.S. Di Paola, et al.
First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy.
J Clin Oncol, 16 (1998), pp. 2392-2400
[22.]
M. Extermann, A. Chen, A.B. Cantor, et al.
Predictors of toxicity from chemotherapy in older patients.
Proc Am Soc Clin Oncol, 19 (2000), pp. 617a
[23.]
E.R. Marcantonio, J.M. Flacker, M. Michaels, et al.
Delirium is independently associated with poor functional recovery after hip fracture.
J Am Ger Soc, 48 (2000), pp. 618-624
[24.]
P.H. Chaves, B. Ashar, J.M. Guralnick, et al.
Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women Should the criteria currently used to define anemia re-evaluated?.
J Am Ger Soc, 50 (2002), pp. 257-264
[25.]
Ferrucci
[26.]
F. Metivier, S.J. Marchais, A.P. Guerin, B. Pannier, G.M. London.
Pathophysiology of anaemia: focus on the heart and blood vessels.
Nephrol Dial Transplant, 15 (2000), pp. 14-18
[27.]
W.C. WU, S.S. Rathore, Y. Wang, et al.
Blood transfusions in elderly patients with acute myocardial infarction.
N Engl J Med, 345 (2001), pp. 1230-1236
[28.]
J.L. Pickett, D.C. Theberge, W.S. Brown, S.U. Schweitzer, A.R. Nissenson.
Normalizing hematocrit in dialysis patients improves brain function.
Am J Kidney Dis, 33 (1999), pp. 1122-1130
[29.]
L.C. Walter Walter, R.J. Brand, S.R. Counsell, et al.
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization.
JAMA, 285 (2001), pp. 2750-2756
[30.]
L.C. Walter, K.E. Covinsky.
Cancer screening in the elderly. A framework for individualized medical decisions.
JAMA, 285 (2001), pp. 2750-2756
[31.]
V. Zagonel, L. Fratino, P. Piselli, et al.
The comprehensive geriatric assessment predicts mortality among elderly cancer patients.
Proc Am Soc Clin Oncol, 21 (2002), pp. 365
[32.]
A. Astani, R.C. Smith, B.J. Allen.
The predictive value of body proteins for chemotherapy induced toxicity.
Cancer, 88 (2000), pp. 796-903
[34.]
L.P. Fried, C.M. Tangen, J. Walston, et al.
Frailty in older adults: evidence for a phenotype.
J Gerontol Med Sci, 56 (2001), pp. M146-M156
[35.]
L. Balducci, G. Stanta.
Cancer in the frail patient: a coming epidemic.
Hematol Oncol Clin N Am, 14 (2000), pp. 235-250
[36.]
K. Rockwood, K. Stadnyk, C. Macknigt, et al.
A brief instrument to classify frailty in elderly people.
Lancet, 353 (1999), pp. 205-206
[37.]
D. Saliba, M. Elliott, L.Z. Rubenstein, et al.
The vulnerable elders survey: a tool for identifying vulnerable older people in the community.
J Am Ger Soc, 49 (2001), pp. 1691-1699
[38.]
T.M. Gill, D.I. Baker, M. Gottschalk, et al.
A program to prevent functional decline in physically frail elderly persons who live at home.
N Engl J Med, 347 (2002), pp. 1068-1074
[39.]
Terret
[40.]
H.J. Cohen, T. Harris, C.F. Pieper.
Coagulation and activation of the inflammation pathway in the development of functional decline and mortality in the elderly.
Am J Med, 114 (2003), pp. 180-187
[41.]
M. Extermann, L. Balducci, G.H. Lyman.
What threshold for adjuvant therapy in older breast cancer patients?.
J Clin Oncol, 18 (2000), pp. 1709-1771
[42.]
Ravdin. Disponible en: www.adjuvantonline.com
[43.]
D. Cova, L. Balducci.
Chemotherapy in the older cancer patient.
Comprehensive geriatric oncology [en prensa],
[44.]
Balducci L, Carreca I. Oral chemotherapy in the elderly
[45.]
J.E. Lancet, C.L. Willman, J.M. Bennett.
Acute myelogenous leukemia and aging: clinical interactions.
Hematol/Oncol Clin N Am, 16 (2000), pp. 251-268
[46.]
C.B. Begg, P. Carbone.
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.
Cancer, 52 (1983), pp. 1986-1992
[47.]
R.S. Gelman, S.G. Taylor.
Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 year oldwith advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance.
J Clin Oncol, 2 (1984), pp. 1406-1414
[48.]
K. Christman, H.B. Muss, D. Case, et al.
Chemotherapy of metastatic breast cancer in the Elderly.
JAMA, 268 (1992), pp. 57-62
[49.]
S. Giovannozzi-Bannon, A. Rademaker, G. Lai, et al.
Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois cancer center study.
J Clin Oncol, 12 (1994), pp. 2447-2452
[50.]
N. Ibrahim, D.K. Frye, A.U. Buzdar, et al.
Doxorubicin based combination chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Arch Intern Med, 156 (1996), pp. 882-888
[51.]
N.K. Ibrahim, A.U. Buzdar, l. Asmar, et al.
Doxorubicin based adjuvant chemotherapy in elderly breast cancer patients: The MD Anderson Experience with long term follow-up.
Ann Oncol, 11 (2000), pp. 1-5
[52.]
L. Balducci, C.L. Hardy, G.H. Lyman.
Hemopoietic growth factors in the older cancer patient.
Curr Opin Hematol, (2001),
[53.]
L. Balducci, L. Repetto.
Increased risk of myelotoxicity in elderly patients with non-Hodgkin's lymphoma.
Cancer, 100 (2004), pp. 6-11
[54.]
M. Extermann, L. Balducci.
Optimizing cancer care in the elderly: progresses in geriatric oncology.
Cancer Control, 10 (2003), pp. 440-452
[55.]
Y.J. Kim, E.B. Rubenstein, K.V. Rolston, et al.
Colony-stimulating factors (CSF) may reduce complications and death in solid tumor patients with fever and neutropenia.
Proc ASCO, 19 (2000), pp. A612
[56.]
D. Crivellari, M. Bonetti, M. Castiglione-Gertsch, et al.
Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: the international breast cancer study group trial VII.
J Clin Oncol, 18 (2000), pp. 1412-1422
[57.]
E.C. Dees, S. O'Reilly, S.N. Goodman, S. Sartorius, M.A. Levin, R.J. Jones, R.C. Donehower, J.H. Fetting.
A prospective pharmacologic evaluation of agerelated toxicity and adjuvant chemotherapy in women with breast cancer.
Cancer Invest, 18 (2000), pp. 521-529
[58.]
P.G. Zinzani, S. Storti, A. Zaccaria, et al.
Elderly aggressive histology non-Hodgkin's lymphoma: first line VNCOP-B regimen: experience on 350 patients.
Blood, 94 (1999), pp. 33-38
[59.]
P. Sonneveld, M. De Ridder, H. Van der Lelie, et al.
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy.
J Clin Oncol, 13 (1995), pp. 2530-2539
[60.]
U. Tirelli, D. Errante, M. Van Glabbeke, et al.
CHOP is the standard regimen in patients. 70 years of age with intermediate and high grade non-Hodgkin's lymphoma: results of a randomized study of the European organization for the Research and Treatment of Cancer Lymphoma Cooperative Study.
J Clin Oncol, 16 (1998), pp. 27-34
[61.]
Y. Bastion, J-Y. Blay, M. Divine, et al.
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years.
J Clin Oncol, 15 (1997), pp. 2945-2953
[62.]
H. Gomez, L. Mas, L. Casanova, et al.
Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocytemacrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity.
J Clin Oncol, 16 (1998), pp. 2352-2358
[63.]
M. Bjorkholm, E. Osby, H. Hagberg, et al.
Proc ASH Blood, 94 (1999), pp. 599
[64.]
J. Doordijin Doordujin, B. Van Der Holt, F. Van Der Kem, et al.
Randomized trial of colony-stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin's lymphoma.
Blood, 96 (2000), pp. 133a
[65.]
V. Morrison, V. Picozzi, S. Scott, et al.
The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Clin Lymph, 2 (2001), pp. 47-56
[66.]
E. Chrischilles, L. Brink, S. Scott, et al.
Factors associated with early termination of CHOP therapy and impact on survival of elderly patients with chemosensitive large cell non Hodkin's lymphoma.
Cancer Control, 9 (2002), pp. 203-211
[67.]
M. Bertini, R. Freilone, U. Vitolo, et al.
The treatment of elderly patients with aggressive non-Hodgkins lymphomas: feasiblity and efficacy of an intensive multidrug regimen.
Leukemia Lymphoma, 22 (1996), pp. 483-493
[68.]
S.D. Jacobson, S. Cha, D.J. Sargent, et al.
Tolerability, dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group Study.
Proc Am Soc Clin Oncol, 20 (2001), pp. 384
Copyright © 2004. Sociedad Española de Geriatría y Gerontología
